Effectiveness of COVID-19 vaccines: findings from real world studies

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

添加到收藏夹

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Equity and evidence during vaccine rollout: stepped wedge cluster randomised trials could help

Katy J. L. Bell et al.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni et al.

Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Jamie Lopez Bernal et al.

Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health